Cargando…

Frequency and clinical impact of hyperkalaemia within a large, modern, real‐world heart failure population

AIMS: This analysis qualitatively describes the impact of hyperkalaemia (HK) and renin‐angiotensin‐aldosterone system inhibitor (RAASi) use on clinical outcomes in patients with heart failure (HF). METHODS AND RESULTS: Patients were included if they were ≥18 years old; had a serum potassium result b...

Descripción completa

Detalles Bibliográficos
Autores principales:	Muhlestein, Joseph B., Kammerer, Jennifer, Bair, Tami L., Knowlton, Kirk U., Le, Viet T., Anderson, Jeffrey L., Lappé, Donald L., May, Heidi T.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Original Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7835576/ https://www.ncbi.nlm.nih.gov/pubmed/33331114 http://dx.doi.org/10.1002/ehf2.13164

Ejemplares similares

Real-world clinical burden and economic assessment associated with hyperkalaemia in a large integrated healthcare system: a retrospective analysis
por: Muhlestein, Joseph B., et al.
Publicado: (2022)

Frequency and Outcomes of Patients Presenting with Non-ST Elevation Myocardial Infarction (NSTEMI) without Standard Modifiable Risk Factors: A US Healthcare Experience
por: Anderson, Jeffrey L., et al.
Publicado: (2023)

Is Alcohol Consumption Associated with a Lower Risk of Cardiovascular Events in Patients Treated with Statins? An Observational Real-World Experience
por: Anderson, Jeffrey L., et al.
Publicado: (2022)

DOES ABO BLOOD GROUP INFLUENCE RISK OR SEVERITY OF COVID-19?
por: Anderson, Jeffrey L., et al.
Publicado: (2021)

Association of periodic fasting with lower severity of COVID-19 outcomes in the SARS-CoV-2 prevaccine era: an observational cohort from the INSPIRE registry
por: Horne, Benjamin D, et al.
Publicado: (2022)

Cardiovascular Outcomes of ST-Elevation Myocardial Infarction (STEMI) Patients without Standard Modifiable Risk Factors (SMuRF-Less): The Intermountain Healthcare Experience
por: Anderson, Jeffrey L., et al.
Publicado: (2022)

Preferential Metabolic Improvement by Intermittent Fasting in People with Elevated Baseline Red Cell Distribution Width: A Secondary Analysis of the WONDERFUL Randomized Controlled Trial
por: Horne, Benjamin D., et al.
Publicado: (2021)

Intermittent fasting and changes in clinical risk scores: Secondary analysis of a randomized controlled trial
por: Horne, Benjamin D., et al.
Publicado: (2023)

A COMPARISON OF CARDIOVASCULAR OUTCOMES AMONG SARS-COV-2 POSITIVE PATIENTS, SARS-COV-2 NEGATIVE PATIENTS, AND A HISTORICAL COHORT
por: May, Heidi Thomas, et al.
Publicado: (2023)

Association of Sociodemographic Factors and Blood Group Type With Risk of COVID-19 in a US Population
por: Anderson, Jeffrey L., et al.
Publicado: (2021)

IMPACT OF THE COVID PANDEMIC ON DEPRESSIVE SYMPTOMS AND SEVERITY
por: May, Heidi Thomas, et al.
Publicado: (2023)

ROUTINE PERIODIC FASTING IS ASSOCIATED WITH A LOWER RISK OF INPATIENT HOSPITALIZATION FOR THE PRIMARY DIAGNOSIS OF HEART FAILURE FOLLOWING COVID-19 DIAGNOSIS
por: Horne, Benjamin Davies, et al.
Publicado: (2023)

Economics and outcomes of sotalol in‐patient dosing approaches in patients with atrial fibrillation
por: Varela, Daniel L., et al.
Publicado: (2022)

Improving CHA(2)DS(2)-VASc stratification of non-fatal stroke and mortality risk using the Intermountain Mortality Risk Score among patients with atrial fibrillation
por: Graves, Kevin G, et al.
Publicado: (2018)

Clinically feasible stratification of 1-year to 3-year post-myocardial infarction risk
por: Horne, Benjamin D, et al.
Publicado: (2018)

Atrial fibrillation is a risk factor for major adverse cardiovascular events in COVID-19
por: Cutler, Michael J., et al.
Publicado: (2022)

Vitamin D supplementation protects against reductions in plasma 25‐hydroxyvitamin D induced by open‐heart surgery: Assess‐d trial
por: Barker, Tyler, et al.
Publicado: (2021)

A new ratio for better predicting future death/myocardial infarction than standard lipid measurements in women >50 years undergoing coronary angiography: the apolipoprotein A1 remnant ratio (Apo A1/ [VLDL(3)+IDL])
por: May, Heidi T, et al.
Publicado: (2013)

Higher docosahexaenoic acid levels lower the protective impact of eicosapentaenoic acid on long-term major cardiovascular events
por: Le, Viet T., et al.
Publicado: (2023)

A Small but Significantly Greater Incidence of Inflammatory Heart Disease Identified After Vaccination for Severe Acute Respiratory Syndrome Coronavirus 2
por: Knowlton, Kirk U, et al.
Publicado: (2021)

Repeated Measurement of the Intermountain Risk Score Enhances Prognostication for Mortality
por: Horne, Benjamin D., et al.
Publicado: (2013)

Association of the Intermountain Risk Score with major adverse health events in patients positive for COVID-19: an observational evaluation of a US cohort
por: Horne, Benjamin D, et al.
Publicado: (2022)

Management of hyperkalaemia in adults.
por: McVeigh, G.
Publicado: (2005)

Hyperkalaemia in Heart Failure
por: Ismail, Umar, et al.
Publicado: (2021)

Severe hyperkalaemia: demographics and outcome
por: Phillips, B.M., et al.
Publicado: (2014)

Surreptitious hyperkalaemia and its complications
por: Morgenstern, Tilo, et al.
Publicado: (2009)

Potassium homoeostasis and pathophysiology of hyperkalaemia
por: Kjeldsen, Keld Per, et al.
Publicado: (2019)

Patiromer sorbitex calcium for hyperkalaemia
Publicado: (2019)

Nafamostat: Hyperkalaemia: case report
Publicado: (2021)

Evaluation of safety, effectiveness and treatment patterns of sodium zirconium cyclosilicate in management of hyperkalaemia in China: a real-world study protocol
por: Shen, Nan, et al.
Publicado: (2023)

Frequency of serum blood glucose monitoring after hyperkalaemia treatment using insulin and dextrose()
por: Aljabri, Ahmed M., et al.
Publicado: (2021)

Hyperkalaemia: aetiology, epidemiology, and clinical significance
por: Tromp, Jasper, et al.
Publicado: (2019)

Suxamethonium-chloride: Hyperkalaemia: case report
Publicado: (2021)

How common is hyperkalaemia? A systematic review and meta-analysis of the prevalence and incidence of hyperkalaemia reported in observational studies
por: Humphrey, Toby, et al.
Publicado: (2021)

Experience with the potassium binder patiromer in hyperkalaemia management in heart failure patients in real life
por: Esteban‐Fernández, Alberto, et al.
Publicado: (2022)

Frequency of laboratory measurement and hyperkalaemia in hospitalised patients using serum potassium concentration increasing drugs
por: Uijtendaal, Esther V., et al.
Publicado: (2011)

Rate-dependent left bundle branch block caused by hyperkalaemia
por: Fransen, N. E., et al.
Publicado: (2016)

Randomized controlled trial of once-per-week intermittent fasting for health improvement: the WONDERFUL trial
por: Bartholomew, Ciera L, et al.
Publicado: (2021)

Sodium Zirconium Cyclosilicate: A Review in Hyperkalaemia
por: Hoy, Sheridan M.
Publicado: (2018)

New treatments for hyperkalaemia: clinical use in cardiology
por: Vijayakumar, Shilpa, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_tmub09mdtkgcjsuuq6gsj7ebq1